STOCKHOLM, May 13, 2024
/PRNewswire/ -- SciBase Holding AB (publ) ("SciBase" or the
"Company") announced that the Company's board of directors
resolved, subject to subsequent approval by the general meeting, on
directed issues of a total of 77,891,769 units consisting of shares
and warrants of series TO 2, with deviation from the shareholders
preferential rights, to a total approximate amount of SEK 33 million (the "Directed Issue"). The
subscription price in the Directed Issue amounted to SEK 0.42 per unit, corresponding to SEK 0.42 per share. The extraordinary general
meeting on 13 May 2024 resolved to
approve the Directed Issue. All units in the Directed Issue have
been subscribed and the board of directors has therefore today, on
13 May 2024, resolved on allotment of
all units in the Directed Issue.
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR
DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG
KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH
AFRICA, THE UNITED STATES
OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART,
WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER
TO BUY SECURITIES IN SCIBASE HOLDING AB (PUBL). SEE ALSO THE
SECTION "IMPORTANT INFORMATION" BELOW IN THIS DOCUMENT.
Allotment of units
All units in the Directed Issue have been subscribed and the board
of directors has therefore today, on 13 May
2024, resolved on allotment of units to Ribbskottet AB, Per
Olof Ejendal AB, Kåre Gilstring, Robert
Molander, MLJK Konsult AB, Klintemar Konsult AB,
Jesper Hoiland, Fredrik Mattsson, Stefan
Hansson, Ulti AB, Van Herk Investments B.V., Matt Leavitt, Viktor
Drvota, Theodor Invest AB, and Eric
Terhaerdt. Ribbskottet AB has chosen to subscribe for
additional units in the Directed Issue by taking over Morningside
Group AB's undertaking to subscribe for units in the Directed
Issue. Thus, Morningside Group AB did not subscribe for and was not
allotted any units in the Directed Issue.
Each unit consists of one (1) share and five (5) warrants of
series TO 2. Through the Directed Issue, SciBase will receive
initial proceeds of approximately SEK 33
million before deduction of transaction costs.
Number of shares and share capital
Through the Directed Issue, the number of shares in SciBase will
increase by 77,891,769 shares, from a total of 141,588,705 shares
(calculated on the total number of shares in the Company after
completion of the announced rights issue) to a total of 219,480,474
shares. Through the Directed Issue, the share capital in the
Company will increase by SEK
3,894,588.45, from SEK
7,079,435.25 (calculated on the Company's share capital
after completion of the announced rights issue) to SEK 10,974,023.70. The Directed Issue entails a
dilution for existing shareholders of approximately 35.5 percent of
the number of shares in the Company. Upon full exercise of the
warrants of series TO 2 issued in the Directed Issue, the Company's
share capital will increase by an additional SEK 19,472,942.25 through the issuance of
389,458,845 new shares entailing an additional dilution effect of
approximately 64.0 percent.
Advisors
Vator Securities is the financial advisor and Advokatfirman
Schjødt is the legal advisor to SciBase in connection with the
Directed Issue.
For additional information, please contact:
Pia Renaudin, VD, tel.
+46732069802, e-mail: pia.renaudin@scibase.com
The information was submitted for publication, through the
agency of the contact persons set out above, at 15.00 CEST on
13 May 2024.
Certified Advisor (CA):
Vator Securities
Tel: +46 8 580 065 99
Email: ca@vatorsec.se
About SciBase:
SciBase is a global medical technology company, specializing in
early detection and prevention in dermatology. SciBase develops and
commercializes Nevisense, a unique point-of-care platform that
combines AI (artificial intelligence) and advanced EIS technology
to elevate diagnostic accuracy, ensuring proactive skin health
management.
Our commitment is to minimize patient suffering, allowing
clinicians to improve and save lives through timely detection and
intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in
dermatological advancements.
The Company has been on the Nasdaq First North Growth Market
exchange since June 2, 2015. Learn
more at www.scibase.com. All press releases and financial reports
can be found
here: http://investors.scibase.se/en/pressreleases
Important information
Publication, release or distribution of this press release may
in certain jurisdictions be subject to legal restrictions and
persons in the jurisdictions where this press release has been made
public or distributed should be informed of and follow such legal
restrictions. The recipient of this press release is responsible
for using this press release and the information herein in
accordance with applicable rules in each jurisdiction. This press
release does not constitute an offer or solicitation to buy or
subscribe for any securities in SciBase in any jurisdiction, either
from SciBase or from anyone else.
This press release is not a prospectus according to the
definition in Regulation (EU) 2017/1129 (the "Prospectus
Regulation") and has not been approved by any regulatory
authority in any jurisdiction. No prospectus has been or will be
prepared in connection with the Directed Issue.
This press release does not constitute an offer or solicitation
to buy or subscribe for securities in the
United States. The securities mentioned herein may not be
sold in the United States without
registration, or without an exemption from registration, under the
U.S. Securities Act from 1933 ("Securities Act") and may not
be offered or sold within the United
States without being registered, covered by an exemption
from, or part of a transaction that is not subject to the
registration requirements according to the Securities Act. There is
no intention to register any securities mentioned herein in
the United States or to issue a
public offering of such securities in the
United States. The information in this press release may not
be released, published, copied, reproduced or distributed, directly
or indirectly, wholly or in part, in or to Australia, Belarus, Canada, Hong
Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South
Africa, the United States
or any other jurisdiction where the release, publication or
distribution of this information would violate current rules or
where such an action is subject to legal restrictions or would
require additional registration or other measures beyond those that
follow from Swedish law. Actions in contravention of this
instruction may constitute a violation of applicable securities
legislation.
Forward-looking statements
This press release contains forward-looking statements related
to the Company's intentions, estimates or expectations with regard
to the Company's future results, financial position, liquidity,
development, outlook, estimated growth, strategies and
opportunities as well as the markets in which the Company is
active. Forward-looking statements are statements that do not refer
to historical facts and can be identified by the use of terms such
as "believes," "expects," "anticipates," "intends," "estimates,"
"will," "may," "implies," "should," "could" and, in each case,
their negative, or comparable terminology. The forward-looking
statements in this press release are based on various assumptions,
which in several cases are based on further assumptions. Although
the Company believes that the assumptions reflected in these
forward-looking statements are reasonable, there is no guarantee
that they will occur or that they are correct. Since these
assumptions are based on assumptions or estimates and involve risks
and uncertainties, actual results or outcomes, for many different
reasons, may differ materially from those what is stated in the
forward-looking statements. Due to such risks, uncertainties,
eventualities and other significant factors, actual events may
differ materially from the expectations that expressly or
implicitly are contained in this press release through the
forward-looking statements. The Company does not guarantee that the
assumptions which serve as a basis for the forward-looking
statements in this press release are correct, and each reader of
the press release should not rely on the forward-looking statements
in this press release. The information, opinions and
forward-looking statements that expressly or implicitly are stated
herein are provided only as of the date of this press release and
may change. Neither the Company nor any other party will review,
update, confirm or publicly announce any revision of any
forward-looking statement to reflect events that occur or
circumstances that arise with respect to the contents of this press
release, beyond what is required by law or Nasdaq First North
Growth Market Rulebook for Issuers of Shares.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/scibase/r/scibase-announces-outcome-in-the-directed-issue-of-units,c3977906
The following files are available for download:
https://mb.cision.com/Main/12371/3977906/2792856.pdf
|
SciBaseAnnouncement of
outcome in directed issue (ENG)
|
View original
content:https://www.prnewswire.co.uk/news-releases/scibase-announces-outcome-in-the-directed-issue-of-units-302143527.html